Stay updated on Navarixin and Pembrolizumab Combination Clinical Trial
Sign up to get notified when there's something new on the Navarixin and Pembrolizumab Combination Clinical Trial page.

Latest updates to the Navarixin and Pembrolizumab Combination Clinical Trial page
- CheckyesterdayChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.6%
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check23 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check30 days agoChange DetectedThe page has added a new publication regarding a phase 2 randomized trial of the CXCR2 antagonist navarixin in combination with pembrolizumab, while the previous version has been deleted due to an erratum.SummaryDifference0.2%
- Check52 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study information regarding the efficacy and safety of navarixin in combination with pembrolizumab for specific solid tumors, and the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference31%
Stay in the know with updates to Navarixin and Pembrolizumab Combination Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Navarixin and Pembrolizumab Combination Clinical Trial page.